EVIO, Inc. (EVIO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
EVIO, Inc. (EVIO) trades at $0.00 with AI Score 47/100 (Grade C). EVIO, Inc. provides analytical testing and advisory services to the cannabis industry in the United States. Market cap: $1.92M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for EVIO: EVIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EVIO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EVIO: the 1 perspectives are evenly split.
How is this calculated? →EVIO, Inc. (EVIO) Healthcare & Pipeline Overview
EVIO, Inc. provides analytical testing and advisory services to the U.S. cannabis industry, offering consulting, product formulation, and comprehensive testing services. With a focus on cannabinoid potency, pesticide screening, and regulatory compliance, EVIO supports cannabis businesses in navigating the complex landscape of the evolving market.
What Is the Investment Thesis for EVIO?
EVIO, Inc. presents a focused play on the cannabis testing and advisory services market. With a P/E ratio of 3.34 and a gross margin of 33.0%, the company demonstrates potential profitability. Growth catalysts include the expansion of cannabis legalization across states, driving demand for testing and compliance services. Key risks include intense competition and the evolving regulatory landscape. Investors should monitor revenue growth, profitability improvements, and the company's ability to adapt to changing regulations in the cannabis industry. The company's beta of 81.01 indicates high volatility.
Based on FMP financials and quantitative analysis
EVIO Key Highlights
- EVIO, Inc. operates in the cannabis analytical testing and advisory services market within the United States.
- The company's profit margin is 3.0%, indicating a potential for improvement in operational efficiency.
- EVIO's gross margin stands at 33.0%, reflecting its ability to manage the cost of services effectively.
- The company's P/E ratio is 3.34, suggesting it may be undervalued compared to its earnings.
- EVIO's beta is 81.01, indicating high volatility compared to the market.
Who Are EVIO's Competitors?
EVIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EVIO's Key Strengths?
- Comprehensive suite of testing and advisory services.
- Expertise in cannabis testing and compliance.
- Established relationships with cannabis businesses.
- Reputation for accuracy and reliability.
What Are EVIO's Weaknesses?
- Small size and limited resources.
- Dependence on the cannabis industry.
- Limited geographic reach.
- High beta indicating high volatility.
What Could Drive EVIO Stock Higher?
- Expansion into new states legalizing cannabis, increasing demand for testing services.
- Increasing regulatory scrutiny in the cannabis industry, driving demand for compliance services.
- Strategic partnerships with cannabis cultivators, processors, and retailers.
What Are the Key Risks for EVIO?
- Negative return on equity (-0.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from other testing labs and consulting firms.
- Evolving regulatory landscape and potential changes in cannabis laws.
- Economic downturn affecting the cannabis industry.
- Limited financial disclosure due to OTC listing.
- Low trading volume and liquidity on the OTC market.
What Are the Growth Opportunities for EVIO?
- Expansion into New Geographies: As more states legalize cannabis, EVIO has the opportunity to expand its testing and advisory services into these new markets. This geographic expansion can significantly increase its revenue base. The timeline for this growth is dependent on the pace of legalization in different states, but it represents a substantial long-term growth opportunity. By establishing testing facilities and building relationships with local cannabis businesses, EVIO can capitalize on the growing demand for its services.
- Development of New Testing Services: EVIO can expand its service offerings to include more specialized testing services, such as heavy metal analysis or genetic testing of cannabis strains. These new services can attract a wider range of customers and increase revenue per client. The timeline for developing these services depends on the availability of technology and expertise, but it represents a valuable opportunity to differentiate EVIO from its competitors. This diversification can enhance EVIO's competitive advantage and market position.
- Strategic Partnerships: Forming strategic partnerships with cannabis cultivators, processors, and retailers can provide EVIO with a steady stream of clients and revenue. These partnerships can also help EVIO expand its geographic reach and service offerings. The timeline for establishing these partnerships depends on the company's ability to build relationships and negotiate favorable terms. However, these partnerships can provide a significant boost to EVIO's growth and profitability.
- Increased Regulatory Scrutiny: As the cannabis industry matures, regulatory scrutiny is likely to increase, driving demand for EVIO's compliance and testing services. This trend presents a significant growth opportunity for the company. The timeline for this growth is dependent on the actions of regulatory bodies, but it is likely to be a long-term trend. By staying ahead of the curve and offering comprehensive compliance solutions, EVIO can position itself as a trusted partner for cannabis businesses.
- Product Formulation and Advisory Services: EVIO can leverage its expertise in cannabis testing to offer product formulation and advisory services to cannabis businesses. This can help these businesses develop new and innovative products that meet regulatory requirements and consumer demand. The timeline for this growth depends on the company's ability to attract and retain talented scientists and consultants, but it represents a valuable opportunity to expand its service offerings and increase revenue.
What Opportunities Does EVIO Have?
- Expansion into new geographic markets.
- Development of new testing services.
- Strategic partnerships with cannabis businesses.
- Increased regulatory scrutiny driving demand for compliance services.
What Threats Does EVIO Face?
- Intense competition from other testing labs and consulting firms.
- Evolving regulatory landscape.
- Potential for changes in cannabis laws.
- Economic downturn affecting the cannabis industry.
What Are EVIO's Competitive Advantages?
- Specialized expertise in cannabis testing and compliance.
- Established relationships with cannabis businesses.
- Comprehensive suite of testing and advisory services.
- Reputation for accuracy and reliability.
What Does EVIO Do?
EVIO, Inc. was established to provide analytical testing and advisory services to businesses operating within the burgeoning cannabis industry in the United States. Recognizing the need for standardized testing and regulatory compliance in this rapidly evolving market, EVIO has positioned itself as a key service provider for cannabis cultivators, processors, and retailers. The company offers a comprehensive suite of services, including consulting, product formulation, and licensing and compliance assistance. Its analytical testing services encompass cannabinoid potency testing, terpene analysis, pesticide testing, residual solvent screening, visual inspections, and biological contaminant testing. These services are designed to ensure product safety, quality, and compliance with state and local regulations. Headquartered in Henderson, Nevada, EVIO, Inc. aims to support the growth and legitimacy of the cannabis industry by providing reliable and accurate testing and advisory solutions.
What Products and Services Does EVIO Offer?
- Provides analytical testing services to the cannabis industry.
- Offers consulting services related to cannabis product formulation.
- Assists cannabis businesses with licensing and compliance.
- Conducts cannabinoid potency testing.
- Performs terpene analysis.
- Screens for pesticides and residual solvents.
- Conducts visual inspections of cannabis products.
- Tests for biological contaminants.
How Does EVIO Make Money?
- Generates revenue through analytical testing services for cannabis products.
- Earns fees from consulting services related to product formulation and regulatory compliance.
- Partnerships with cannabis cultivators, processors, and retailers.
- Offers specialized testing services, such as heavy metal analysis and genetic testing.
What Industry Does EVIO Operate In?
EVIO, Inc. operates within the rapidly expanding cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance across the United States. The market for cannabis testing and advisory services is becoming increasingly important as regulations tighten and consumers demand safer, more reliable products. Competition is intensifying, with numerous testing labs and consulting firms vying for market share. EVIO's success depends on its ability to maintain high standards of accuracy, compliance, and customer service in this dynamic environment.
Who Are EVIO's Key Customers?
- Cannabis cultivators
- Cannabis processors
- Cannabis retailers
- Cannabis product manufacturers
F-Score 3/9Financial Health
EVIO, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE -0%Key Financial Metrics
Return on equity for EVIO, Inc. stands at -0.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.7%, showing how much profit it generates from its asset base. EVIO trades at a trailing price-to-earnings ratio of 1.67, below the Healthcare sector average of ~23x. Its free cash flow yield is -74.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 59.8%, the inverse of the P/E and a quick read on earnings relative to price.
EVIO, Inc. (EVIO) Valuation Context
Valued at $1.92M, EVIO is classified as a micro-cap stock. Relative to its peer group, EVIO's quantitative score of 47/100 is below the peer average of 66/100.
EVIO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see value, potentially signaling confidence in future prospects.
- The community buzz seems optimistic, with many highlighting potential catalysts for growth in the near term.
- Market perception is shifting, with increasing recognition of the company's strategic positioning within its sector.
- Positive developments in the industry are creating tailwinds that could benefit the company's overall performance.
Bear Case
- Lack of significant insider selling would be more reassuring, the absence raises questions about long-term commitment.
- Despite some positive sentiment, a significant portion of the community remains skeptical, citing concerns about execution.
- Market perception is still mixed, with some analysts questioning the sustainability of recent gains.
- Industry headwinds, such as increased competition, could present challenges to the company's growth trajectory.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EVIO Latest News
-
The Strait of Hormuz is more open than previously thought as the U.S. shoots down Iranian drones threatening ships and provides ‘naval overwatch’
Fortune | FORTUNE · Jun 7, 2026
-
EVIO Teams with Molicel to Advance Energy Storage Development
businesswire.com · May 21, 2026
EVIO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EVIO.
Price Targets
Wall Street price target analysis for EVIO.
EVIO MoonshotScore
What does this score mean?
The MoonshotScore rates EVIO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lori Jean Glauser
CEO
Lori Jean Glauser serves as the CEO of EVIO, Inc. Her background includes experience in managing and growing businesses, with a focus on strategic planning and execution. She has demonstrated leadership in navigating complex regulatory environments and building strong teams. Her expertise is crucial for guiding EVIO through the evolving cannabis industry landscape. She is responsible for overseeing all aspects of the company's operations and driving its growth strategy.
Track Record: Under Lori Jean Glauser's leadership, EVIO, Inc. has focused on expanding its testing and advisory services to meet the growing demand in the cannabis industry. She has overseen the development of new testing capabilities and the expansion of the company's geographic reach. Her strategic decisions have aimed to position EVIO as a trusted partner for cannabis businesses seeking to ensure product safety and regulatory compliance. She manages 18 employees.
EVIO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that EVIO, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available to the public, and trading activity may be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Higher price volatility
- Potential for fraud or manipulation
- Lack of regulatory oversight
- Verify the company's financial statements.
- Research the company's management team and their track record.
- Assess the company's competitive position in the cannabis testing market.
- Review the company's regulatory filings and compliance history.
- Evaluate the company's growth prospects and expansion plans.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Operational testing facilities and advisory services.
- Partnerships with established cannabis businesses.
- Compliance with state and local regulations.
- Positive customer reviews and testimonials.
- Experienced management team.
What Investors Ask About EVIO, Inc. (EVIO) — Healthcare
What does EVIO, Inc. do?
EVIO, Inc. provides analytical testing and advisory services to businesses operating in the cannabis industry. The company offers a range of services, including cannabinoid potency testing, terpene analysis, pesticide screening, and residual solvent testing. Additionally, EVIO provides consulting services related to product formulation, licensing, and regulatory compliance. By ensuring product safety and regulatory adherence, EVIO supports the growth and legitimacy of the cannabis market.
What do analysts say about EVIO stock?
As of 2026-03-17, formal analyst ratings for EVIO are limited, likely due to its OTC listing and smaller market capitalization. Key valuation metrics include a P/E ratio of 3.34 and a gross margin of 33.0%. Growth considerations revolve around the expansion of cannabis legalization and the increasing demand for testing and compliance services. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for EVIO?
The main risks for EVIO include intense competition in the cannabis testing market, the evolving regulatory landscape, and potential changes in cannabis laws. The company's OTC listing also presents risks related to limited financial disclosure, low trading volume, and higher price volatility. Additionally, an economic downturn could negatively impact the cannabis industry and reduce demand for EVIO's services. Investors should carefully consider these risks before investing in EVIO.
What are the key factors to evaluate for EVIO?
EVIO, Inc. (EVIO) holds an AI score of 47/100 (low). Not financial advice.
How frequently does EVIO data refresh on this page?
EVIO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EVIO's recent stock price performance?
EVIO, Inc. (EVIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive suite of testing and advisory services. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EVIO overvalued or undervalued right now?
Valuing EVIO, Inc. (EVIO) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying EVIO?
Before investing in EVIO, Inc. (EVIO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing.
- AI analysis pending for EVIO.